Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Philadelphia Chromosome 2Leukemia 2Myeloproliferative Disorders 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Hematologic Diseases 1

Interventions

Imatinib Mesylate 5nilotinib 4bosutinib 3asciminib 2peginterferon alfa-2a 1fludarabine phosphate 1fludarabine 1Magnetic Resonance Imaging 1Electrocardiography 1Echocardiography 1Diphenhydramine 1Dasatinib 1Cyclophosphamide 1Blood Component Removal 1Antiemetics 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Philadelphia Chromosome × asciminib × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05456191 2026-05-27

ASC4START

Novartis

Phase 3 Active not recruiting
568 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡